title: Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
abstract: Chronic L-3,4-dihydroxyphenylalanine (L-DOPA) treatment of Parkinson's disease induces in time numerous side effects, such as abnormal involuntary movements called L-DOPA-induced dyskinesias (LIDs). An involvement of glutamate transmission, dopamine transmission and opioid transmission in striatal output pathways has been hypothesized for the induction of LIDs. Interestingly, our previous experiments indicated that some striatal δ-opioid receptors are located on terminals of glutamatergic corticostriatal neurons and that stimulation of these receptors modulates the release of glutamate and dopamine. The present study was performed to test the involvement of δ-opioid receptors, and more precisely of those located on corticostriatal neurons, in abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats. The effects of a selective agonist, [D-Pen(2), D-Pen(5)]-enkephalin (DPDPE) and a selective antagonist (naltrindole) of δ-opioid receptors on LIDs were investigated in animals submitted or not to a corticostriatal deafferentation. Our results indicate that DPDPE and naltrindole respectively enhanced and reduced LIDs in animals in which the ipsilateral cortex was preserved intact. However, the lesion of the ipsilateral cortex prevented the stimulant effect of DPDPE on LIDs. The [(3)H]-DPDPE binding to striatal membranes prepared from the whole striatum was also studied. A significant increase in density of δ-opioid receptors was found in the striatum of dyskinetic animals as compared to non-dyskinetic animals but this difference was abolished by the corticostriatal deafferentation. These results indicate that δ-opioid transmission modulates the expression of LIDs in rodents and suggest that the δ-opioid receptors involved in this effect are located on terminals of corticostriatal neurons.
authors.affiliation: Experimental Neuropsychopharmacology Laboratory (EA 4359), University and Hospital Institute of Biomedical Research, University of Rouen, IFR23, 76183 Rouen, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Billet
authors.forename: Jean
authors.initials: J
authors.lastname: Costentin
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dourmap
mesh_terms: D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism / Q000633:toxicity*; D004409:Dyskinesia, Drug-Induced / Q000378:metabolism* / Q000503:physiopathology; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000378:metabolism; D007980:Levodopa / Q000627:therapeutic use / Q000633:toxicity*; D008297:Male; D009474:Neurons / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D011485:Protein Binding / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000502:physiology*
chemical_list: D017465:Receptors, Opioid, delta; D007980:Levodopa; D020881:Enkephalin, D-Penicillamine (2,5)-; D004298:Dopamine